Tiba Biotech has been selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation – JLABS (‘JLABS’) and the Biomedical Advanced Research and Development Authority (‘BARDA’), to apply our next-generation nucleic acid delivery technology to develop new products that can guard against and respond to public health threats.
Tiba Biotech was mentioned in the recent edition of THE VIRAL MOST WANTED, a series of articles by the Coalition for Epidemic Preparedness Innovations (CEPI), highlighting progress toward the development of next generation flavivirus vaccines.
In a study published in Science Immunology, University of Minnesota researchers in collaboration with colleagues at Tiba Biotech and Emory University, demonstrated that nasal delivery of Tiba's RNABL vaccine induced adaptive immune responses in the respiratory tracts of mice.
Tiba’s co-founder and mRNA visionary, Christian Mandl, spoke at the Global Vaccine and Immunization Research Forum 2021, the central forum for research related to the Immunization Agenda 2030 (IA2030). GVIRF is the only global meeting that brings together the entire Vaccine and Immunization Research community, from basic immunology to implementation research, and from low to high income countries.
© 2024 Tiba Biotech LLC. All rights reserved
